Jeremy

Overall a high-quality compounder, but these overhangs are capping near-term upside.

Capital Deployment Pressure — $188B deployable capital. Need to deploy wisely without overpaying in a competitive environment. Wealth Solutions Execution — Ambitious $5.5B DE target by 2030, but integration risks and rate sensitivity add near-term uncertainty.

$BN has several overhangs weighing on the stock right now: High Valuation & Expectations — Trading at a premium. Market demands consistent strong performance; any “just okay” quarter leads to selling.

Question to Mark Miller on why he elected not to be paid a salary or bonus after being promoted to President: “I’m just continuing what Mark Leonard did, I want to help and do what’s best for shareholders.” $CSU.to

Overall, the business fundamentals are still healthy and growing fast, but the pace of profit growth slowed due to higher credit costs and investments. This is a classic growth company trade-off: investing aggressively now for future scale.

There are concerns over MELI vs NU in terms of fintech area. So far, Nu is winning on pure banking/fintech metrics with faster revenue growth, much higher profit, and a significantly larger customer base. They are the clear leader in digital banking in LatAm. Will monitor this.

$NU delivered record results on several fronts: Revenue crossed $5 billion for the first time (+53% YoY). Net income reached $871 million (+41% YoY). Customers hit 135 million (+4 million added in the quarter).

Long-term thesis remains intact: Constellation continues to be one of the best capital allocators in software, with a proven ability to compound through acquisitions in fragmented vertical markets.

The jump in net income/EPS looks impressive but is partly driven by the lumpy nature of their business. The real story is the ongoing compounding through disciplined M&A, the introduction of PEMS for larger deals, and early AI efforts across the portfolio.

$CNSWF This was a typical Constellation quarter: strong revenue growth, excellent cash flow, noisy margins due to acquisition timing, and continued execution on their buy-and-build model.

@mike98572986 @netoventures got it. thankyou

@netoventures @chivarse think you need something with Stifel wealth

$clpt Highly recommend getting a hold of the May 8th Stifel Analyst report on Clearpoint, a lot of nuggets in there with exactly what we have been talking about for years. Best report I have seen from an analyst on clearpoint from a competitive advantage perspective/moat.

@mike98572986 do u knw where to get it?

Overall, ClearPoint delivered +43% revenue growth in Q1, led by strong performance in Navigation & Laser Therapy. Nothing exciting or special, to me it's just as planned.

3. Laser Therapy & Access→ Prism Laser system for minimally invasive brain procedures (growing fast) 4. Neurocritical Care & Active CSF Exchange→ Managing fluid in ICU brain patients (emerging pillar)

$CLPT 4 Strategic Pillars (Q1 2026): Pre-commercial Biologics & Drug Delivery→ Delivering gene therapies & drugs directly into the brain (huge long-term potential) Neurosurgery Navigation & Robotics→ Their core “GPS for the brain” business — currently the main revenue driver